References
- Sotiriadis A, Papatheodorou S, Makrydimas G. Threatened miscarriage: evaluation and management. BMJ. 2004;329(7458):1–7. doi: 10.1136/bmj.329.7458.152.
- Qureshi NS. Treatment options for threatened miscarriage. Maturitas. 2009;65 Suppl 1:S35–S41. doi: 10.1016/j.maturitas.2009.10.010.
- Everett C. Incidence and outcome of bleeding before the 20th week of pregnancy: prospective study from general practice. BMJ. 1997;315(7099):32–34. doi: 10.1136/bmj.315.7099.32.
- Saraswat L, Bhattacharya S, Maheshwari A, et al. Maternal and perinatal outcome in women with threatened miscarriage in the first trimester: a systematic review. BJOG. 2010;117(3):245–257. doi: 10.1111/j.1471-0528.2009.02427.x.
- Aleman A, Althabe F, Belizán J, et al. Bed rest during pregnancy for preventing miscarriage. Cochrane Database Syst Rev. 2005;2005(2):CD003576. doi: 10.1002/14651858.CD003576.pub2.
- Mirza FG, Patki A, Pexman-Fieth C. Dydrogesterone use in early pregnancy. Gynecol Endocrinol. 2016;32(2):97–106. doi: 10.3109/09513590.2015.1121982.
- Patel B, Elguero S, Thakore S, et al. Role of nuclear progesterone receptor isoforms in uterine pathophysiology. Hum Reprod Update. 2015;21(2):155–173. doi: 10.1093/humupd/dmu056.
- Pařízek A, Koucký M, Dušková M. Progesterone, inflammation and preterm labor. J Steroid Biochem Mol Biol. 2014;139:159–165. doi: 10.1016/j.jsbmb.2013.02.008.
- Schindler AE, Campagnoli C, Druckmann R, et al. Classification and pharmacology of progestins. Maturitas. 2008;61(1-2):171–180. doi: 10.1016/j.maturitas.2008.11.013.
- El-Zibdeh MY, Yousef LT. Dydrogesterone support in threatened miscarriage. Maturitas. 2009;65 Suppl 1: S43–S6. doi: 10.1016/j.maturitas.2009.11.013.
- Omar MH, Mashita MK, Lim PS, et al. Dydrogesterone in threatened abortion: pregnancy outcome. J Steroid Biochem Mol Biol. 2005;97(5):421–425. doi: 10.1016/j.jsbmb.2005.08.013.
- Pandian RU. Dydrogesterone in threatened miscarriage: a Malaysian experience. Maturitas. 2009;65 Suppl 1:S47–S50. doi: 10.1016/j.maturitas.2009.11.016.
- Chan DMK, Cheung KW, Ko JKY, et al. Use of oral progestogen in women with threatened miscarriage in the first trimester: a randomized double-blind controlled trial. Hum Reprod. 2021;36(3):587–595. doi: 10.1093/humrep/deaa327.
- Yassaee F, Shekarriz-Foumani R, Afsari S, et al. The effect of progesterone suppositories on threatened abortion: a randomized clinical trial. J Reprod Infertil. 2014;15(3):147–151.
- Alimohamadi S, Javadian P, Gharedaghi MH, et al. Progesterone and threatened abortion: a randomized clinical trial on endocervical cytokine concentrations. J Reprod Immunol. 2013;98(1–2):52–60. doi: 10.1016/j.jri.2013.01.004.
- Gerhard I, Gwinner B, Eggert-Kruse W, et al. Double-blind controlled trial of progesterone substitution in threatened abortion. Biol Res Pregnancy Perinatol. 1987;8(1 1ST Half):26–34.
- McLindon LA, James G, Beckmann MM, et al. Progesterone for women with threatened miscarriage (STOP trial): a placebo-controlled randomized clinical trial. Hum Reprod. 2023;38(4):560–568. doi: 10.1093/humrep/dead029.
- Coomarasamy A, Harb HM, Devall AJ, et al. Progesterone to prevent miscarriage in women with early pregnancy bleeding: the PRISM RCT. Health Technol Assess. 2020;24(33):1–70. doi: 10.3310/hta24330.
- Coomarasamy A, Devall AJ, Cheed V, et al. A randomized trial of progesterone in women with bleeding in early pregnancy. N Engl J Med. 2019;380(19):1815–1824. doi: 10.1056/NEJMoa1813730.
- Yovich JL, Mariappen U, Hinchliffe PM, et al. MPA given orally during the first trimester for threatened miscarriage carries no specific risk for foetal abnormalities albeit the rate is higher than non-threatened pregnancies. Reprod Biol. 2020;20(3):424–432. doi: 10.1016/j.repbio.2020.03.008.
- Progestogens for preventing miscarriage: ectopic pregnancy and miscarriage: diagnosis and initial management: evidence review C. NICE Evidence Reviews Collection. London2021.